Compare Amylx Pharmaceuticals Inc (AMLX) vs Chewy Inc (CHWY) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Chewy (CHWY) trades at $20.88, up 1.02% today, but remains under pressure with a bearish technical signal and recent earnings misses. The company reported strong revenue growth to $11.86B in 2025 and improved net income of $393M, yet faces margin compression and lowered FY26 sales guidance. Analyst sentiment remains overwhelmingly positive with 81.58% buy ratings and a $34.92 consensus target, suggesting significant upside potential from current levels despite near-term challenges.

The investment case balances attractive valuation metrics (P/S 0.69) against cyclical headwinds and competitive pressures. While operational cash flow growth and market share gains in pet healthcare provide long-term catalysts, investor caution is warranted given recent guidance reductions and volatile technical positioning near key support levels.